212 related articles for article (PubMed ID: 2271921)
1. Chronic neurochemical and behavioral changes in MPTP-lesioned C57BL/6 mice: a model for Parkinson's disease.
Sundström E; Fredriksson A; Archer T
Brain Res; 1990 Oct; 528(2):181-8. PubMed ID: 2271921
[TBL] [Abstract][Full Text] [Related]
2. Social enrichment attenuates nigrostriatal lesioning and reverses motor impairment in a progressive 1-methyl-2-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of Parkinson's disease.
Goldberg NR; Fields V; Pflibsen L; Salvatore MF; Meshul CK
Neurobiol Dis; 2012 Mar; 45(3):1051-67. PubMed ID: 22198503
[TBL] [Abstract][Full Text] [Related]
3. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism.
Rozas G; López-Martín E; Guerra MJ; Labandeira-García JL
J Neurosci Methods; 1998 Sep; 83(2):165-75. PubMed ID: 9765130
[TBL] [Abstract][Full Text] [Related]
4. Nanomolar L-dopa facilitates release of dopamine via presynaptic beta-adrenoceptors: comparative studies on the actions in striatal slices from control and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mice, an animal model for Parkinson's disease.
Goshima Y; Misu Y; Arai N; Misugi K
Jpn J Pharmacol; 1991 Jan; 55(1):93-100. PubMed ID: 1645816
[TBL] [Abstract][Full Text] [Related]
5. Behavioral effects of dopamine agonists and antagonists in MPTP-lesioned D3 receptor knockout mice.
Yarkov AV; Hanger D; Reploge M; Joyce JN
Pharmacol Biochem Behav; 2003 Dec; 76(3-4):551-62. PubMed ID: 14643855
[TBL] [Abstract][Full Text] [Related]
6. Effects of R- and S-apomorphine on MPTP-induced nigro-striatal dopamine neuronal loss.
Grünblatt E; Mandel S; Maor G; Youdim MB
J Neurochem; 2001 Apr; 77(1):146-56. PubMed ID: 11279270
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on striatal dopamine receptor system.
Lau YS; Fung YK
Brain Res; 1986 Mar; 369(1-2):311-5. PubMed ID: 3486026
[TBL] [Abstract][Full Text] [Related]
8. Morphological, neurochemical, and behavioral characterizations associated with the combined treatment of diethyldithiocarbamate and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in mice.
Yurek DM; Deutch AY; Roth RH; Sladek JR
Brain Res; 1989 Sep; 497(2):250-9. PubMed ID: 2573405
[TBL] [Abstract][Full Text] [Related]
9. [A mouse model of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induced parkinsonism: effect of norepinephrine terminal destruction].
Nishi K; Kondo T; Narabayashi H
No To Shinkei; 1987 Jul; 39(7):663-72. PubMed ID: 3314916
[TBL] [Abstract][Full Text] [Related]
10. [Recovery of nigrostriatal and mesolimbic dopaminergic system following administration of ganglioside in MPTP-treated mice].
Date I; Asari S; Nishimoto A; Felten DL
No To Shinkei; 1990 Nov; 42(11):1035-40. PubMed ID: 2076347
[TBL] [Abstract][Full Text] [Related]
11. Long-term effect of MPTP in the mouse brain in relation to aging: neurochemical and immunocytochemical analysis.
Date I; Felten DL; Felten SY
Brain Res; 1990 Jun; 519(1-2):266-76. PubMed ID: 1975765
[TBL] [Abstract][Full Text] [Related]
12. The effects of chronic levodopa treatment on pre- and postsynaptic markers of dopaminergic function in striatum of parkinsonian monkeys.
Rioux L; Frohna PA; Joyce JN; Schneider JS
Mov Disord; 1997 Mar; 12(2):148-58. PubMed ID: 9087972
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys.
Falardeau P; Bouchard S; Bédard PJ; Boucher R; Di Paolo T
Eur J Pharmacol; 1988 May; 150(1-2):59-66. PubMed ID: 3261249
[TBL] [Abstract][Full Text] [Related]
14. Alterations in striatal and extrastriatal D-1 and D-2 dopamine receptors in the MPTP-treated common marmoset: an autoradiographic study.
Gnanalingham KK; Smith LA; Hunter AJ; Jenner P; Marsden CD
Synapse; 1993 Jun; 14(2):184-94. PubMed ID: 8332947
[TBL] [Abstract][Full Text] [Related]
15. Effects of blocking the dopamine biosynthesis and of neurotoxic dopamine depletion with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) on voluntary wheel running in mice.
Leng A; Mura A; Hengerer B; Feldon J; Ferger B
Behav Brain Res; 2004 Oct; 154(2):375-83. PubMed ID: 15313025
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism.
Kozina EA; Khakimova GR; Khaindrava VG; Kucheryanu VG; Vorobyeva NE; Krasnov AN; Georgieva SG; Kerkerian-Le Goff L; Ugrumov MV
J Neurol Sci; 2014 May; 340(1-2):198-207. PubMed ID: 24768159
[TBL] [Abstract][Full Text] [Related]
17. Neuroprotective effects of stemazole in the MPTP-induced acute model of Parkinson's disease: Involvement of the dopamine system.
Guo Z; Xu S; Du N; Liu J; Huang Y; Han M
Neurosci Lett; 2016 Mar; 616():152-9. PubMed ID: 26827716
[TBL] [Abstract][Full Text] [Related]
18. [Therapeutic effect of a natural squamosamide derivative FLZ on Parkinson's disease model mice induced by LPS plus MPTP].
Yu LH; Wei HL; Bao XQ; Zhang D; Sun H
Yao Xue Xue Bao; 2013 Oct; 48(10):1557-62. PubMed ID: 24417082
[TBL] [Abstract][Full Text] [Related]
19. Regulation by D2 dopamine receptors of in vivo dopamine synthesis in striata of rats and mice with experimental parkinsonism.
Richard MG; Bennett JP
Exp Neurol; 1994 Sep; 129(1):57-63. PubMed ID: 7925842
[TBL] [Abstract][Full Text] [Related]
20. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment.
Elsworth JD; Taylor JR; Sladek JR; Collier TJ; Redmond DE; Roth RH
Neuroscience; 2000; 95(2):399-408. PubMed ID: 10658619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
